2.60
price up icon1.17%   0.03
after-market アフターアワーズ: 2.57 -0.03 -1.15%
loading
前日終値:
$2.57
開ける:
$2.51
24時間の取引高:
100,000
Relative Volume:
0.45
時価総額:
$20.09M
収益:
-
当期純損益:
$-32.54M
株価収益率:
-13.00
EPS:
-0.2
ネットキャッシュフロー:
$-29.06M
1週間 パフォーマンス:
-6.81%
1か月 パフォーマンス:
-38.79%
6か月 パフォーマンス:
-83.76%
1年 パフォーマンス:
-86.84%
1日の値動き範囲:
Value
$2.48
$2.74
1週間の範囲:
Value
$2.44
$2.85
52週間の値動き範囲:
Value
$2.44
$26.75

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name
名前
Citius Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
(908) 967-6676
Name
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Name
職員
22
Name
Twitter
Name
次回の収益日
2024-08-12
Name
最新のSEC提出書
Name
CTXR's Discussions on Twitter

CTXR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CTXR
Citius Pharmaceuticals Inc
2.60 20.09M 0 -32.54M -29.06M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-11-30 開始されました Maxim Group Buy

Citius Pharmaceuticals Inc (CTXR) 最新ニュース

pulisher
Dec 19, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada

Dec 18, 2024
pulisher
Dec 17, 2024

Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com

Dec 17, 2024
pulisher
Dec 11, 2024

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 06, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

Dec 06, 2024
pulisher
Nov 30, 2024

Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com

Nov 30, 2024
pulisher
Nov 28, 2024

Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com

Nov 28, 2024
pulisher
Nov 27, 2024

Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com

Nov 27, 2024
pulisher
Nov 27, 2024

Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com

Nov 27, 2024
pulisher
Nov 27, 2024

Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com

Nov 27, 2024
pulisher
Nov 27, 2024

Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 27, 2024
pulisher
Nov 27, 2024

Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR

Nov 27, 2024
pulisher
Nov 27, 2024

Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com

Nov 27, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits - Quantisnow

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharma progresses with FDA on Mino-Lok approval By Investing.com - Investing.com Nigeria

Nov 26, 2024
pulisher
Nov 26, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital - Defense World

Nov 26, 2024
pulisher
Nov 25, 2024

Citius Pharma progresses with FDA on Mino-Lok approval - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - PR Newswire

Nov 25, 2024
pulisher
Nov 25, 2024

Citius Pharma shares hit new low after reverse stock split - Kursiv Media

Nov 25, 2024
pulisher
Nov 24, 2024

Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR) - Defense World

Nov 24, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split - citybiz

Nov 22, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - The Malaysian Reserve

Nov 22, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals announces 1-for-25 reverse stock split - MSN

Nov 22, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.16 By Investing.com - Investing.com Australia

Nov 22, 2024
pulisher
Nov 21, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com India

Nov 21, 2024
pulisher
Nov 20, 2024

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve

Nov 15, 2024
pulisher
Nov 15, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024

Citius Pharmaceuticals Inc (CTXR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Citius Pharmaceuticals Inc (CTXR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Webb Carol
Director
Mar 04 '24
Option Exercise
0.01
12,071
181
12,071
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):